FAQ: What Causes Generic Drug Shortages?

The Federal Food, Drug, and Cosmetic Act defines a drug shortage as a period during which the demand or anticipated demand for a drug in the United States exceeds its available supply.¹

In practice, these supply deficits go beyond an inventory problem. They force healthcare professionals into difficult real-time adjustments, like strict drug allocation, substitution with alternative therapies, and delays in patient treatment. The downstream consequences are especially acute in hospital settings, where clinical protocols often depend on the consistent availability of low-cost generics. Because generic medicines account for the majority of US prescriptions, any breakdown in supply creates outsized disruption, interrupting clinical continuity, straining pharmacy operations, and, in the most severe cases, contributing to medication errors or missed doses.

What Are the Main Causes of Generic Drug Shortages?

Generic drug shortages rarely stem from a single failure point. They typically emerge from a convergence of manufacturing disruptions, economic pressure, and supply chain fragility operating simultaneously. When examining root causes, the leading operational triggers are manufacturing infrastructure failures, quality compliance problems, and unsustainable product economics.

The broader economic ecosystem compounds these vulnerabilities. Intense price competition in the generic market, often characterized as a race to the bottom, has driven significant supplier consolidation over time, leaving fewer companies actively producing any given product. With the market thinned out, redundancy is minimal: when fewer suppliers remain, even a single production disruption can cascade into widespread national supply gaps.

The challenge ultimately comes down to the economics of the system. Hospital budgets have grown tighter, buyer consolidation has intensified, and prices for generic injectables have been driven down to the point where continued market participation is sometimes no longer sustainable for manufacturers.

How Do Manufacturing Quality Issues and Regulatory Compliance Contribute to Supply Gaps?

Manufacturing quality problems are among the most common triggers of sudden market exits. Generic pharmaceuticals, particularly sterile injectables used in acute-care settings, require complex, specialized production processes that must comply with the FDA's Current Good Manufacturing Practice regulations. When an inspection uncovers a compliance failure, such as microbial contamination, particulate matter in vials, or systemic equipment degradation, the manufacturer must often halt production or initiate large-scale product recalls.

Because profit margins on these drugs are low, manufacturers rarely invest in upgrading aging infrastructure or building redundant production lines. Consequently, when a facility is forced offline by a regulatory action, there is no cushion. Other market participants are often already operating at or near full capacity and cannot rapidly absorb the additional demand. A single regulatory intervention at a dominant plant can therefore trigger an immediate, prolonged national shortage.

How Do Purchasing Dynamics and Low-Margin Economics Impact Long-Term Supply Sustainability?

Retail Pharmacy procurement is dominated by four buying groups comprising over 90% market share: Red Oak, Walgreens Boots Alliance, ClarusOne and Econdisc. Hospital procurement is largely shaped by three large GPO’s: Vizient, HPG, and Premier, and they drive contracting and wholesaler distribution models that prioritize price compression and volume leverage.²

While efficient in lowering costs, this structure leaves little room for margin recovery in mature generics, particularly low-cost injectables. Over time, sustained price deflation discourages investment in redundancy, quality upgrades, and capacity resilience. As suppliers rationalize portfolios or exit marginal products, supply becomes increasingly concentrated. This creates a system where procurement efficiency improves on the surface, but underlying supply durability weakens, making disruptions more likely and harder to absorb.

Why Doesn’t Supply Recover Immediately After Manufacturing Restarts?

Restarting production resolves the root disruption but does not address the imbalance created during the shortage period. Many drugs have either one or two suppliers. Any damage to the supply chain leads to inventory pipelines being depleted, and demand accumulates across hospitals, distributors, and backorders. Initial production runs are therefore absorbed by accrued demand rather than restoring normal availability. In parallel, regulatory clearances, batch release cycles, and distribution prioritization introduce additional lag. The result is a structural delay between manufacturing normalization and actual recovery of product availability at the hospital level.

Do Drug Shortages Impact All Health Systems Equally?

Shortages are distributed unevenly across the healthcare landscape, with impact closely tied to purchasing scale, contracting position, and geographic access. Large IDNs and well-aligned systems often receive prioritized allocation due to volume commitments and established supply relationships. In contrast, smaller IDNs, independent hospitals, and providers in tier-2 or remote geographies tend to operate with limited leverage and thinner inventory buffers.³ As a result, supply disruptions disproportionately affect these segments, leading to longer access gaps despite similar clinical need. This uneven distribution highlights that shortages are not just supply problems, but access and allocation problems within the system.

What Role Does Global Supply Chain Concentration Play?

The structural fragility of the generic drug market is further amplified by the geographic concentration of pharmaceutical manufacturing. Producing a finished generic drug depends on a multi-tiered global network: raw starting materials, Active Pharmaceutical Ingredients, and finished dosage formulation. Over recent decades, the drive toward lowest-cost production has centralized the majority of API manufacturing and raw material sourcing in a small number of international regions.

This concentration introduces systemic risk, with more than 80% of APIs produced overseas. If a primary API facility experiences a localized crisis — whether an environmental regulatory shutdown, a natural disaster, or geopolitical trade friction — the entire downstream market for that drug faces an immediate bottleneck. US manufacturers that rely on single-source international partners find themselves unable to secure necessary raw materials. Because registering a new API supplier involves a lengthy and costly regulatory approval process, domestic manufacturers cannot swiftly pivot to alternatives, turning a localized overseas disruption into an extended domestic shortage.

As an IQVIA analysis of US drug shortage dynamics found, more than three-quarters of active shortages occur in highly concentrated markets, including single-source products, where a disruption at the leading or sole supplier can result in a prolonged shortage, given the significant lead time required for any new or existing company to build or expand capacity.⁴

How Do Price Deflation and Economics Prevent Market Recovery?

Beyond physical manufacturing and geography, the commercial purchasing structures of the US pharmaceutical market create dynamics that can inadvertently suppress market recovery. The entry of multiple competitors into a generic drug space typically triggers substantial price cuts, sometimes reducing a drug's value to a small fraction of the original brand-name price.

Market volatility, low pricing, and compressed profit margins create a highly challenging economic environment for generic drug manufacturers. Driven by intense price competition and unpredictable revenue streams, companies must simultaneously manage the high capital investments required to maintain mature quality systems. These economic pressures often force cost-reductions to unsustainable levels, push existing suppliers out of the market, and discourage new entrants—even for products experiencing active shortages.⁵

While this system reduces costs for consumers and payers, it can simultaneously create conditions where essential products are sold below sustainable cost levels.

This environment leads directly to poor market entry and retention economics. Manufacturers sometimes elect not to launch FDA-approved generics when prevailing prices cannot cover production overhead. For drugs already in shortage, a substantial proportion have at least one approved generic alternative that remains entirely unlaunched.

What Is the Current State of the US Generic Drug Market?

While generic medicines form the backbone of the American healthcare ecosystem—accounting for nearly 90% of all prescriptions filled—they represent a mere 12% of total domestic drug spending. This extreme pricing imbalance has created a highly fragile operational landscape.

Because generic drugs are frequently subject to deflationary purchasing structures and intense price competition, profit margins for mature products are continually compressed. When multiple competitors enter a market, prices can drop by 70% to 80% relative to the original brand-name price, frequently driving the cost of essential generic injectables below $5 per unit.

Consequently, market shortages are heavily concentrated at the bottom of the pricing spectrum: medications priced under $1 per extended unit account for approximately 56% of active domestic shortages.

References

1. U.S. Food and Drug Administration. (n.d.). Frequently asked questions about drug shortages. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
2. Frank, R. G., & Zehe, M. (2023, June 21). When cheap becomes fragile: How the race-to-the-bottom in generics undermines manufacturing quality and what to do about it. Brookings Institution. https://www.brookings.edu/articles/when-cheap-becomes-fragile-how-the-race-to-the-bottom-in-generics-undermines-manufacturing-quality-and-what-to-do-about-it/
3. Sani, Zainab Nimma, and Barbara Aryeley Aryee. “Optimizing Drug Supply Chains to Prevent Shortages in Rural U.S. Hospitals.” EPRA International Journal of Multidisciplinary Research, Sept. 2025, https://doi.org/10.36713/epra24022.
4. IQVIA Institute for Human Data Science. (2023, November). Drug shortages in the US 2023: Trends, causes, and mitigation strategies. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/drug-shortages-in-the-us-2023/drug-shortages-in-the-us-2023.pdf
5. Office of the Assistant Secretary for Planning and Evaluation. (2024, April). Mitigating drug shortages: Supply chain vulnerabilities and policy responses [White Paper]. U.S. Department of Health and Human Services. https://aspe.hhs.gov/sites/default/files/documents/3a9df8acf50e7fda2e443f05d51d038/HHS-White-Paper-Preventing-Shortages-Supply-Chain-Vulnerabilities.pdf